Clinical Trial Update: Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for PTI-428 evaluating safety, tolerability, and pharmacokinetics in cystic fibrosis subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• PTI-428

Snippet

Sponsor: Proteostasis Therapeutics, Inc. | Conditions: Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED